Nebulized Sub-dissociative Dose Ketamine for Treating Pain
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The investigators previous research study comparing the efficacy of intravenous ketamine to
morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in
emergency department patients. A second study by the investigators showed that increasing the
time of administration of the ketamine, from a push injection to a drip infusion, will
minimize the adverse effects experienced by recipients of ketamine.
The investigators now aim to see if nebulized subdissociative-dose ketamine administered as a
single agent in a dose of 1.5 mg/kg via Breath-Actuated Nebulizers (BAN) over 5-15 minutes
will provide a better pain relief in comparison to 1 mg/kg and 0.75 mg/kg doses or if the
lower doses are equally as effective.